We have determined the mutational specificity of the 5-nitrofuran derivative furylfuramide (AF2) in the lacI gene of Escherichia coli. Treatment of a delta uvrB, pKM101 strain with 1 M AF2 yielded a mutation frequency approximately 300 times greater than that of untreated controls. Of the 165 AF2-induced mutants analysed by DNA sequencing, 145 were base substitution mutations, 11 were frameshifts, and the remainder small deletions, tandem base substitutions and complex mutations. Base substitution occurred primarily (greater than 93%) at G:C base pairs. The proportions of the various mutations are very similar to those that have been reported for AP sites. We suggest that the principal mechanism for AF2 mutagenesis is the formation of an adduct which depurinates to yield AP sites that serve as a substrate for error-prone repair. Seventy-two of the mutations occurred at four 5'-TGC-3' sites. The majority (10/11) of the frameshift mutations occurred at one such hotspot and could have been templated by an inverted repeat less than 100 bp removed from the site of the mutation.

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/12.1.29DOI Listing

Publication Analysis

Top Keywords

mutational specificity
8
af2 laci
8
laci gene
8
gene escherichia
8
escherichia coli
8
base substitution
8
mutations occurred
8
mutations
5
specificity 2-2-furyl-3-5-nitro-2-furyl-acrylamide
4
af2
4

Similar Publications

Aims: This study aims to identify and evaluate promising therapeutic proteins and compounds for breast cancer treatment through a comprehensive database search and molecular docking analysis.

Background: Breast cancer (BC), primarily originating from the terminal ductal-lobular unit of the breast, is the most prevalent form of cancer globally. In 2020, an estimated 2.

View Article and Find Full Text PDF

Background: Doravirine is licensed in patients living with HIV (PWH) harbouring no prior resistance to any NNRTIs. We aimed to evaluate in real life the efficacy of doravirine with prior NNRTI virological failure and NNRTI resistance-associated mutations (RAMs).

Methods: This observational study included PWH switched to a doravirine-containing regimen between 30 September 2019 and 1 May 2022, with an HIV-1 RNA of ≤50 copies/mL and past NNRTI-RAMs.

View Article and Find Full Text PDF

MOANA: Multi-objective ant nesting algorithm for optimization problems.

Heliyon

January 2025

Centre for Artificial Intelligence Research and Optimisation, Torrens University, Brisbane, QLD, 4006, QLD 4006, Austral, Australia.

This paper presents the Multi-Objective Ant Nesting Algorithm (MOANA), a novel extension of the Ant Nesting Algorithm (ANA), specifically designed to address multi-objective optimization problems (MOPs). MOANA incorporates adaptive mechanisms, such as deposition weight parameters, to balance exploration and exploitation, while a polynomial mutation strategy ensures diverse and high-quality solutions. The algorithm is evaluated on standard benchmark datasets, including ZDT functions and the IEEE Congress on Evolutionary Computation (CEC) 2019 multi-modal benchmarks.

View Article and Find Full Text PDF

Background: TG02 is a peptide-based cancer vaccine eliciting immune responses to oncogenic codon 12/13 mutations. This phase 1 clinical trial (NCT02933944) assessed the safety and immunological efficacy of TG02 adjuvanted by GM-CSF in patients with -mutant colorectal cancer.

Methods: In the interval between completing CRT and pelvic exenteration, patients with resectable mutation-positive, locally advanced primary or current colorectal cancer, received 5-6 doses of TG02/GM-CSF.

View Article and Find Full Text PDF

Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development.

ACS Med Chem Lett

January 2025

Discovery Biology, PMV Pharmaceuticals, Inc., 400 Alexander Park Drive, Suite 301, Princeton, New Jersey 08540, United States.

p53 is a potent transcription factor that is crucial in regulating cellular responses to stress. Mutations in the gene are found in >50% of human cancers, predominantly occurring in the DNA-binding domain (amino acids 94-292). The Y220C mutation accounts for 1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!